As an Associate in the Healthcare vertical, Conor helps the team review and analyze prospective investment opportunities and present recommendations, focusing on the firm’s Identified Sector Opportunities (ISOs). He also collaborates with the Strategic Resource Group and portfolio company management to support existing investments through the next phase of growth.

Before joining the THL team, Conor worked at TripleTree as an Investment Banking Analyst. Outside of work, he spends his time playing soccer and making music.

Verticals
Healthcare (HC)
Verticals
Healthcare (HC)

Related content

Why We Invested in Celerion: Advancing the Future of Clinical Pharmacology
Insights
Why We Invested in Celerion: Advancing the Future of Clinical Pharmacology 

Key Takeaways: In April 2026, THL announced a majority investment in Celerion, a global leader in clinical pharmacology and bioanalytical sciences that supports pharmaceutical and biotechnology companies in advancing new therapies through critical stages of clinical development. As drug development becomes increasingly complex — driven by novel therapeutic modalities, precision medicine, and evolving regulatory requirements — clinical

Healthcare (HC)

Want to learn more?